5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.83▼ | 4.90▼ | 4.90▼ | 4.81▼ | 4.79▲ |
MA10 | 4.86▼ | 4.88▼ | 4.86▼ | 4.81▼ | 4.93▼ |
MA20 | 4.83▼ | 4.83▼ | 4.83▼ | 4.84▼ | 5.06▼ |
MA50 | 4.83▼ | 4.83▼ | 4.85▼ | 5.08▼ | N/A |
MA100 | 4.84▼ | 4.96▼ | 5.04▼ | 5.33▼ | N/A |
MA200 | 5.04▼ | 5.00▼ | 5.12▼ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.008▼ | 0.006▲ | 0.009▲ | 0.007▲ | -0.427▼ |
RSI | 47.000▼ | 46.138▼ | 46.232▼ | 46.628▼ | 48.494▼ |
STOCH | 29.880 | 65.426 | 66.667 | 40.764 | 33.768 |
WILL %R | -80.000▼ | -80.000▼ | -80.000▼ | -73.684 | -58.961 |
CCI | -64.442 | -67.568 | -54.493 | -14.638 | -7.777 |
Tuesday, June 03, 2025 06:15 AM
ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to ...
|
Tuesday, May 13, 2025 07:35 AM
By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2b Trial of Halneuron® in CINP underway; Interim Results Expected in 4Q25 Dogwood Therapeutics, Inc ...
|
Monday, May 12, 2025 08:17 PM
By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2b Trial of Halneuron® in CINP underway; Interim Results Expected in 4Q25 Dogwood Therapeutics, Inc ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
03/07/25 | 4.81 | 4.88 | 4.75 | 4.80 | 12,767 |
02/07/25 | 5.00 | 5.00 | 4.83 | 4.83 | 36,108 |
01/07/25 | 4.80 | 5.00 | 4.7545 | 4.95 | 25,682 |
30/06/25 | 4.71 | 4.8683 | 4.71 | 4.77 | 4,575 |
27/06/25 | 4.86 | 4.86 | 4.66 | 4.71 | 14,969 |
26/06/25 | 4.82 | 4.82 | 4.71 | 4.77 | 16,339 |
25/06/25 | 4.7201 | 4.85 | 4.7201 | 4.80 | 12,609 |
24/06/25 | 4.77 | 4.895 | 4.71 | 4.85 | 14,714 |
23/06/25 | 4.96 | 4.96 | 4.7501 | 4.76 | 13,455 |
20/06/25 | 4.71 | 5.00 | 4.71 | 4.90 | 46,549 |
|
|
||||
|
|
||||
|
|